Global Lung Cancer Treatment Market Set to Reach US$ 73.29 Billion by 2033 Driven by Precision Medicine, Immunotherapy, and Next-Gen ADCs | Top Companies are Merck & Co., Inc., Pfizer Inc., AstraZeneca

The global lung cancer treatment market size reached US$ 32.64 billion in 2024 and is expected to reach US$ 73.29 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

The Global Lung Cancer Treatment market encompasses therapies including chemotherapy, targeted therapy, immunotherapy, and surgery for lung cancer patients. Rising incidence of lung cancer and smoking-related diseases drives demand. Innovations in precision medicine, immunotherapy, and minimally invasive procedures improve outcomes. Increased healthcare spending and access to advanced treatments further fuel growth. Ongoing R&D and clinical trials support continued development of novel therapies.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Global Lung Cancer Treatment Market Landscape:- https://datamintelligence.com/download-sample/lung-cancer-treatment-market?rk

✅ Recently Approved / Late-Stage
Datroway (datopotamab deruxtecan) - TROP2-targeting ADC; approved in U.S. for advanced NSCLC after prior therapy.

Ivonescimab (AK112 / SMT112) - Bispecific antibody (PD-1 + VEGF-A); approved in China, Phase III trials in U.S. for NSCLC.

Nuvalent's TKIs (zidesamtinib, neladalkib) - Targeting ROS1+ and ALK+ NSCLC with resistance mutations; Phase 1/2 data expected 2025.

HER2 inhibitors (e.g., zongertinib / BI 1810631) - HER2 mutation-directed TKIs; Phase III (Beamion LUNG-2) ongoing.

Telisotuzumab vedotin (ABBV-399) - c-Met-targeting ADC for NSCLC with c-Met overexpression; moving toward pivotal studies.

Tarlatamab (IMDELLTRA®) - DLL3-targeting BiTE for small-cell lung cancer (SCLC); accelerated U.S. approval in 2024.

Edolitinib (TY-9591) - Next-gen EGFR inhibitor effective in brain metastases; Phase II trial vs osimertinib.

🚀 Emerging / Early-Phase
IBI363 - PD-1/IL-2α fusion protein (bispecific); FDA fast-track for squamous NSCLC post-immunotherapy + chemo.

ICP-189 + furmonertinib - SHP2 inhibitor + EGFR TKI combo for resistant EGFR mutations.

Lifileucel (LN-145) - TIL (tumour-infiltrating lymphocyte) therapy for NSCLC relapsed after PD-1 blockade.

🔑 Key Trends
Resistance management focus - Drugs designed for patients failing EGFR/ALK inhibitors.

Rise of ADCs & bispecific antibodies - Targeting TROP2, c-Met, PD-1/VEGF, DLL3.

Brain metastases addressed - New EGFR inhibitors (e.g., edolitinib) trialed for CNS activity.

Rare mutation targets - HER2, ROS1, ALK, uncommon EGFR mutations.

SCLC innovation - BiTE therapies (e.g., tarlatamab) offering new hope beyond chemotherapy.

☛ Global Lung Cancer Treatment Market Competitve Landscape:

Merck & Co., Inc., Pfizer Inc., AstraZeneca, Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceuticals U.S.A., Inc., Amneal Pharmaceuticals LLC., Genentech USA, Inc., Rigel Pharmaceuticals, Inc., Daiichi Sankyo, Inc. and among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/lung-cancer-treatment-market

☛ Segment Covered in the Global Lung Cancer Treatment Market:

By Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma, Squamous Cell Carcinoma, Large Cell (Undifferentiated) Carcinoma, Others, Small Cell Lung Cancer (SCLC), Lung Carcinoid Tumors, Others

By Treatment Type: Chemotherapy, Gemcitabine, Docetaxel, Etoposide, Paclitaxel, Others, Radiation Therapy, Targeted Therapy, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates (ADCs), Angiogenesis Inhibitors, Others, Surgery

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Global Lung Cancer Treatment Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=lung-cancer-treatment-market

☛ Regional Analysis for Global Lung Cancer Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Global Lung Cancer Treatment Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Global Lung Cancer Treatment Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Global Lung Cancer Treatment Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.